Increased midgestational IFN-γ, IL-4 and IL-5 in women bearing a child with autism: A case-control study.

Goines PE, Croen LA, Braunschweig D, Yoshida CK, Grether J, Hansen R, Kharrazi M, Ashwood P, Van de Water J. · 2011

Read Increased midgestational IFN-γ, IL-4 and IL-5 in women bearing a child with autism: A case-control study. by Goines PE, Croen LA, Braunschweig D, Yoshida CK, Grether J, Hansen R, Kharrazi M, Ashwood P, Van de Water J. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3170586.txt.

Introduction

Paula Goines and colleagues measured immune signals in stored pregnancy blood from mothers whose children later received developmental diagnoses in a 2011 paper in Molecular Autism. Immune oddities are common in autistic people and their families, but whether the mother's pregnancy immune state relates to risk was unknown. Samples came from the middle weeks of pregnancy, years before diagnosis.

Three signals ran high in mothers of autistic children, a profile tied to roughly half again higher odds of autism, regardless of onset type or intellectual disability. A different trio of raised signals marked mothers of children with developmental delay but not autism. The split profiles suggest distinct prenatal immune patterns for distinct outcomes, worth tracing for their effects on the developing brain.

Catalog record

CREATORGoines PE, Croen LA, Braunschweig D, Yoshida CK, Grether J, Hansen R, Kharrazi M, Ashwood P, Van de Water J.
YEAR2011
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3170586

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Increased midgestational IFN-γ, IL-4 and IL-5 in women bearing a child with autism: A case-control study By Paula E Goines, Lisa A Croen, Daniel Braunschweig, Cathleen K Yoshida, Judith Grether, Robin Hansen, Martin Kharrazi, Paul Ashwood, Judy Van de Water Published in: Molecular Autism DOI: 10.1186/2040-2392-2-13 ABSTRACT Abstract Background Immune anomalies have been documented in individuals with autism spectrum disorders (ASDs) and their family members. It is unknown whether the maternal immune profile during pregnancy is associated with the risk of bearing a child with ASD or other neurodevelopmental disorders. Methods Using Luminex technology, levels of 17 cytokines and chemokines were measured in banked serum collected from women at 15 to 19 weeks of gestation who gave birth to a child ultimately diagnosed with (1) ASD (n = 84), (2) a developmental delay (DD) but not autism (n = 49) or (3) no known developmental disability (general population (GP); n = 159). ASD and DD risk associated with maternal cytokine and chemokine levels was estimated by using multivariable logistic regression analysis. Results Elevated concentrations of IFN-γ, IL-4 and IL-5 in midgestation maternal serum were significantly associated with a 50% increased risk of ASD, regardless of ASD onset type and the presence of intellectual disability. By contrast, elevated concentrations of IL-2, IL-4 and IL-6 were significantly associated with an increased risk of DD without autism. Conclusion The profile of elevated serum IFN-γ, IL-4 and IL-5 was more common in women who gave birth to a child subsequently diagnosed with ASD. An alternative profile of increased IL-2, IL-4 and IL-6 was more common for women who gave birth to a child subsequently diagnosed with DD without autism. Further investigation is needed to characterize the relationship between these divergent maternal immunological phenotypes and to evaluate their effect on neurodevelopment. BACKGROUND Autism spectrum disorders (ASDs) are a heterogeneous group of neurodevelopmental diseases that manifest in early childhood. Individuals with ASD demonstrate varying degrees of social impairments, deficits in language and communication and stereotypic and repetitive behaviors [1]. There are no clear biological markers for ASD, and current diagnosis relies entirely on behavioral criteria [2,3]. Little is known about the pathology and etiology of the disorders, though genetic, neurologic, environmental and/or immune factors are likely involved [4]. Recent epidemiologic data suggest that approximately 1 in 100 children is diagnosed with an ASD [5,6], highlighting the urgent need for better understanding of this complex disorder. Evidence has linked various types of maternal immune activation and dysregulation to behavioral disorders, including ASD [7,8]. Mothers of children with ASD have been reported to have a higher incidence of allergic and autoimmune diseases compared to mothers of typically developing children [9-11]. Furthermore, some mothers harbor circulating antibodies that can bind to brain proteins [12-15]. Prenatal immune challenge, such as a bacterial or viral infection, has also been related to behavioral disorders in offspring in both epidemiological studies and animal models [16]. Murine models have shown that exposure to influenza [17], lipopolysaccharide (LPS) [18] and polyinosinic:polycytidylic acid (poly(I:C)) [17,19] during pregnancy results in offspring with altered behavioral phenotypes and brain histopathology, which may be related to aspects of ASD. The impact of maternal immune activation on the fetal compartment is mediated in part by cytokines and chemokines [7,18,19]. Cytokines and chemokines are proteins that control the intensity, duration and type of immune response. Prenatal exposure to altered levels of cytokines such as IL-2 [20] and IL-6 [21] is sufficient to induce learning disabilities and behavioral changes in murine offspring. Maternal cytokines may affect the fetal compartment directly, as IL-6 has been shown to cross the human placenta (unlike many other cytokines) [22], or indirectly through stimulation of placental cells, which may alter the placental environment and thereby impact the fetus [7]. Few studies have examined midgestational cytokine levels in mothers and ensuing behavioral outcomes in children. We conducted a case-control study using archived maternal blood samples collected during the period from 15 to 19 weeks of gestation to investigate the potential association between serum cytokine profiles and the risk of bearing a child subsequently diagnosed with a neurodevelopmental disorder. We demonstrate the presence of divergent cytokine profiles in serum taken during the second trimester of pregnancy from mothers bearing (1) a child with ASD, (2) a child with a developmental delay (DD) other than ASD or (3) a child from the general population with no known developmental deficiencies (GP). METHODS Subjects The study sample was based on the Early Markers for Autism (EMA) Study. The EMA Study is a population-based, nested case-control study designed to evaluate biologic markers of susceptibility and exposure in archived maternal midpregnancy and neonatal blood specimens from the same mother-baby pairs. The study subjects are women residing in Orange County, California, who were pregnant in 2000 and 2001 and enrolled in the state's Prenatal Expanded AFP Screening Program [15]. Briefly, three groups were identified: mothers of children with autism spectrum disorder (ASD), mothers of children with DD but not ASD and mothers of GP children. Children with ASD or DD were ascertained from client records obtained from the Regional Center of Orange County. This is one of the 21 regional centers operated by the California Department of Developmental Services (DDS), which are designed to coordinate services for persons with autism and other developmental disabilities. Clients receiving DDS services for ASD or suspected ASD were ascertained as possible subjects for inclusion in this study. Other subjects with moderate to profound developmental disabilities but not ASD (specifically children with an IQ <70 based on standardized tests) were ascertained as other possible DD cases. Diagnoses were confirmed by expert review of all ASD and DD cases as described in the next subsection. GP controls were randomly sampled from the birth certificate files and frequency-matched to ASD cases by sex, birth month and birth year at a 2:1 ratio. All past or current DDS/regional center clients were excluded from the GP population. All study procedures were approved by the institutional review boards of the California Health and Human Services Agency and Kaiser Permanente Northern California. Diagnostic verification After subjects were ascertained from the Regional Center Orange County, ASD and DD diagnoses were verified by trained medical record abstractors following a protocol initially developed by the Metropolitan Atlanta Developmental Disabilities Surveillance Program [23]. Medical record abstractors compiled detailed diagnostic and clinical data from the Regional Center Orange County records for all children initially ascertained as possibly having ASD or DD. Expert clinical review of abstracted data was then conducted by a developmental pediatrician to confirm the ASD or DD diagnoses for this study using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. Children with ASD were further categorized on the basis of disease onset type and cognitive status (presence or absence of intellectual disability (ID) in addition to ASD) using the DSM-IV criteria. Onset type was determined by parental report or clinical observations derived from chart reviews and categorized as "early" (no statement of loss of social and/or language skills, or skill plateau without actual loss), "regressive" (clear loss of previously acquired language and/or social skills) or unable to discern from the record review. The ID determination among ASD subjects was based on composite scores on standardized cognitive

Read the complete text